WASHINGTON — Safeguards to protect patients from risky drugs should have less paperwork and more consistency, drugmakers and pharmacy representatives said this week during a U.S. Food and Drug Administration meeting.
The drug industry acknowledged the benefit of so-called risk evaluation and mitigation strategies, or REMS, a set of disclosure and educational tools to protect consumers from drugs with potentially serious side effects.
But it is requesting a lighter regulatory touch. The FDA said it would consider some changes.
via msnbc.msn.com
No comments:
Post a Comment